Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

Table 3

Hematological and nonhematological toxicities.

	AE (G3/4)	Docetaxel + placebo	Docetaxel + PPV
Hematologic	Leukocytopenia	33.3%	46.2%
	Neutrocytopenia	100.0%	76.9%
	Lymphocytopenia	4.2%	0%
	FN	4.2%	3.8%
Nonhematologic	Appetite loss	4.2%	0%
	Neuropathy	4.2%	0%
	Infection	4.2%	0%
	ILD	4.2%	7.7%
Injection related	Skin reaction (G1/2)	16.7%	50.0%

FN, febrile neutrocytopenia; ILD, interstitial lung disease.